AKT1 and neoplasm: Capivasertib, a selective AKT inhibitor, has been demonstrated to enhance the anti-tumor effects of docetaxel by targeting residual docetaxel-resistant cells, irrespective of PTEN status, thereby inducing apoptosis and DNA damage[18].